Testing all women over 30 for faulty malignancy genes ‘will spend less and save lives’ Research backs blanket screening process for breasts, ovarian cancers mutations
Only those with a family history of the condition are now examined for cancer-causing mistakes in their BRCA1 and BRCA2 genes.
New research shows that more than 80,000 conditions of tumors could be avoided if ALL female over the age of 30 were offered screening for gene mutations.
According to experts from Barts Cancer tumor Institute at Queen Mary University or college of London and Barts Health NHS Trust, employing a program for examining all United kingdom women over 30 years old could result in far fewer instances of ovarian and breasts malignancy; almost 17,000 fewer ovarian malignancies and 64,000 reduced breast cancers.
Research workers in London have found that screening the whole populace for the gene could also be more cost-effective, as our Technology Editor Tom Clarke information. “Our findings support broadening hereditary testing for breast and ovarian tumor genes across the whole human population beyond just the existing criteria based clinical approach”